Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppressi...